Treatment modalities in cancer-associated venous thromboembolism (VTE).

Javier Soto Alsar, Ana Gutiérrez Ortiz de la Tabla, Laura Ortega Morán, Andrés J Muñoz Martín

Journal: Best practice & research. Clinical haematology 2022;35(1):101354

PMID: 36030074

Full Text on Elsevier Science View on PubMed

Abstract

Anticoagulation is the cornerstone of cancer-associated VTE treatment, including vitamin K antagonists (VKA), unfractionated heparin (UFH), fondaparinux, low-molecular-weight heparins (LMWH) and direct oral anticoagulants (DOACs). The goals of anticoagulant therapy in cancer patients with cancer-associated thrombosis (CAT) are to improve symptoms, reduce risk of recurrent VTE or fatal pulmonary embolism (PE), and decrease the risk of post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension. Although LMWH have been the standard of care for a long time for VTE treatment in cancer patients, showing superiority over the classic VKA, in the recent years the landscape of anticoagulant therapy has significantly changed with the inclusion of DOACs in this population.

Address: Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain; Cancer & Thrombosis Section, Spanish Society of Medical Oncology (SEOM), Spain.; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain; Cancer & Thrombosis Section, Spanish Society of Medical Oncology (SEOM), Spain. Electronic address: [email protected].

DOI: 10.1016/j.beha.2022.101354

Link outs

Free resources

Medical:

https://medlineplus.gov/cancer.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-472

Subscription / membership required

Full Text Sources:

MeSH Terms: Anticoagulants, Heparin, Heparin, Low-Molecular-Weight, Humans, Neoplasms, Venous Thromboembolism